DOD Biotech Return On Equity vs. Operating Margin

DOD Stock   1.95  0.01  0.51%   
Considering the key profitability indicators obtained from DOD Biotech's historical financial statements, DOD Biotech Public may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess DOD Biotech's ability to earn profits and add value for shareholders.
For DOD Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DOD Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DOD Biotech Public utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DOD Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DOD Biotech Public over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
Please note, there is a significant difference between DOD Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if DOD Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DOD Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

DOD Biotech Public Operating Margin vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining DOD Biotech's current stock value. Our valuation model uses many indicators to compare DOD Biotech value to that of its competitors to determine the firm's financial worth.
DOD Biotech Public is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in operating margin category among its peers reporting about  2.61  of Operating Margin per Return On Equity. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DOD Biotech's earnings, one of the primary drivers of an investment's value.

DOD Operating Margin vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

DOD Biotech

Return On Equity

 = 

Net Income

Total Equity

 = 
0.04
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

DOD Biotech

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.10 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

DOD Operating Margin Comparison

DOD Biotech is currently under evaluation in operating margin category among its peers.

DOD Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on DOD Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DOD Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DOD Biotech's important profitability drivers and their relationship over time.

Use DOD Biotech in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DOD Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DOD Biotech will appreciate offsetting losses from the drop in the long position's value.

DOD Biotech Pair Trading

DOD Biotech Public Pair Trading Analysis

The ability to find closely correlated positions to DOD Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DOD Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DOD Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DOD Biotech Public to buy it.
The correlation of DOD Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DOD Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DOD Biotech Public moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DOD Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your DOD Biotech position

In addition to having DOD Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Business Supplies Thematic Idea Now

Business Supplies
Business Supplies Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Business Supplies theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Business Supplies Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in DOD Stock

To fully project DOD Biotech's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DOD Biotech Public at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DOD Biotech's income statement, its balance sheet, and the statement of cash flows.
Potential DOD Biotech investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although DOD Biotech investors may work on each financial statement separately, they are all related. The changes in DOD Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DOD Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.